div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 15button div class=ts-image amp-img class=ts-thumb alt=Page 15: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails15jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 16button div class=ts-image amp-img class=ts-thumb alt=Page 16: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails16jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 17button div class=ts-image amp-img class=ts-thumb alt=Page 17: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails17jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 18button div class=ts-image amp-img class=ts-thumb alt=Page 18: Nonclinical assessment of abuse potential of new pharmaceuticals src=https:reader030vdocumentsusreader030viewer20220215005873a6dc1a28aba3548b5129html5thumbnails18jpg width=142 height=106 layout=responsive amp-img divdiv